HSV-1 is a significant human pathogen that can result in the loss of sight as a result of episodic reactivation of latent virus from sensory ganglion neurons. In this study the potential efficacy of anti-viral cytokine expression in preventing latent virus reactivation was investigated. Both type I (IFN-β) and type II (IFN-γ) IFN transgene expression following transduction of trigeminal ganglion explant cultures significantly reduced the incident of HSV-1 reactivation that in the case of IFN-β was dependent on the presence of double stranded RNA-dependent protein kinase and RNase L. In vivo, expression of the IFN-γ but not IFN-β transgene significantly delayed and reduced the frequency of reactivation of latent mice exposed to UV light without discernable inflammation. This result is the first report that demonstrates the ability to block reactivation using an ectopic cytokine expression system and warrants further exploration as a means to prevent HSV-1 reactivation.
Introduction
HSV-1 establishes a lifelong persistence in human and mouse trigeminal ganglion (TG) neurons where spontaneous molecular reactivation is thought to occur (Croen et al., 1987; Stevens et al., 1987; Feldman et al., 2002) . Spontaneous or incomplete reactivation has been found to result in a persistent localized immune response in the corresponding ganglia (Shimeld et al., 1995; Cantin et al., 1995; Liu et al., 1996; Halford et al., 1996a; Theil et al., 2003) . In vitro and in vivo studies have found that CD8 + T lymphocytes are principally involved in maintenance of latent HSV-1 infection within the TG (Noisakran and Carr, 1999; Liu et al., 2000; Khanna et al., 2003; Sheridan et al., 2006) . Although the mechanism involved in reactivation from latency is not understood, IL-6 has been tied to facilitating reactivation (Kriesel et al., 1997; Noisakran et al., 1998) whereas IFN-γ expressed by CD8 + T cells has been reported to antagonize reactivation associated with a reduction in ICP0 expression in the neurons undergoing reactivation (Cantin et al., 1999; Decman et al., 2005) . Type I (IFN-αs and IFN-β) and type II (IFN-γ) IFNs are potent anti-viral cytokines that block virus replication through the induction of the JAK/ STAT pathway eliciting the production of Mx proteins, double-stranded RNA-dependent protein kinase (PKR), and the oligoadenylate synthetase effector molecule, RNase L (Stark et al., 1998; Torterella et al., 2000) . The importance of these anti-viral pathways in the prevention of HSV-1 replication is underscored by the action of HSV-1-encoded proteins that specifically target IFN-induced pathways and effector molecules counteracting the anti-viral effect (Chou et al., 1995; Mossman and Smiley, 2002; Yokota et al., 2004; Halford et al., 2006) . In addition to the anti-viral properties induced by IFNs, type I IFNs facilitate the development of the adaptive immune response through the activation of dendritic cells (Biron, 2001; Le Bon et al., 2003) which in terms of viral infection promote CD8 + T cell clonal expansion and memory cell formation (Kolumam et al., 2005) . Against this background, we sought to determine to what extent IFNs could antagonize latent HSV-1 reactivation. Since previous results reported success in delivery of the IFN transgenes by adenovirus (Ad) vector and hindering acute HSV-1 infection (Austin et al., 2005 (Austin et al., , 2007 , we chose to compare IFN-γ to the most efficacious type I IFN transgene, IFN-β (Härle et al., 2002) , in preventing HSV-1 reactivation in an in vitro and in vivo model. To the best of our knowledge, this is the first report Journal of Neuroimmunology 206 (2009) 39-43 
